Executive Interview: Gitte Aabo On Leo Pharma's Innovation Strategy

The head of Denmark's multinational specialty dermatology company has unveiled a strategy to the year 2025 that includes a large increase in R&D spending, a continued interest in bulking up its established products business, and improving its commercial presence in Latin America and other markets.

Wounds
Skin conditions like atopic dermatitis are the focus of Leo Pharma • Source: Shutterstock

The president and CEO of Leo Pharma AS, Gitte Aabo, is convinced the years up to 2025 will see remarkable progress in the treatment of dermatological diseases, including the development of gene technologies to cure rare skin diseases, the use of biologics in atopic dermatitis to rival the benefits of such drugs in psoriasis seen over the past decade, and the application of precision medicine to the therapeutic area.

Through participating in such breakthroughs, Leo is aiming to become the global leader in the dermatology space, rivalling larger companies...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Dermatological

More from Therapeutic Category